Compounds and methods for inhibiting mitotic progression

Patent metadata

Field	Value
Publication number	US-9765078-B2
Application number	US-201514810225-A
Country	US
Kind code	B2
Filing date	Jul 27, 2015
Priority date	May 14, 2004
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

First claim

What is claimed is:

1. A process for preparing a compound of formula (A-1):

or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;
Ring B is a substituted or unsubstituted aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;
Ring C is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;
R e is hydrogen, —OR 5 , —N(R 4 ) 2 , —SR 5 , or a C 1-3 aliphatic optionally substituted with R 3 or R 7 ;
each of R x and R y independently is hydrogen, fluoro, or an optionally substituted C 1-6 aliphatic; or R x and R y , taken together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloaliphatic ring;
each R 3 independently is selected from the group consisting of halo, —OH, —O(C 1-3 alkyl), —CN, —N(R 4 ) 2 , —C(O)(C 1-3 alkyl), —CO 2 H, —CO 2 (C 1-3 alkyl), —C(O)NH 2 , and —C(O)NH(C 1-3 alkyl);
each R 4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R 4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;
each R 5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; and
each R 7 independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group;
said process comprising step (e) of:
heating a compound of formula (x):

with a cyclodehydration reagent to afford the compound of formula (A-1).

2. The process of claim 1 , wherein the compound of formula (A-1) is a compound of formula (Va):

wherein:
R e is hydrogen;
each of R b2 and R b3 independently is selected from the group consisting of hydrogen, halo, C 1-3 aliphatic, C 1-3 fluoroaliphatic, and —OR 5 , where R 5 is hydrogen or C 1-3 aliphatic; and
each of R c1 and R c5 independently is selected from the group consisting of hydrogen, halo, C 1-3 aliphatic, C 1-3 fluoroaliphatic, and —OR 5 , where R 5 is hydrogen or C 1-3 aliphatic;
R g is selected from the group consisting of hydrogen, C 1-6 aliphatic, and R 2d ; and
each of R h and R k independently is hydrogen or R d .

3. The process of claim 2 , wherein each of R g , R h , and R k independently is selected from the group consisting of hydrogen, C 1-3 aliphatic, halo, —OR 5 , —CO 2 R 5 , —C(O)N(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —C(═NR 4 )N(R 4 ) 2 , —C(O)N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 )—C(O)R 5 , and —N(R 4 )C(O)R 5 .

4. The process of claim 2 , wherein R g is hydrogen, and at least one of R h and R k is selected from the group consisting of —CO 2 R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )N(R 4 ) 2 , —C(O)N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 )—C(O)R 5 , and —N(R 4 )C(O)R 5 .

5. The process of claim 1 , further comprising step (d), prior to step (e), of treating a compound of formula (ix):

with
(i) an acid chloride in the presence of a base; or
(ii) a carboxylic acid in the presence of a coupling reagent

to afford the compound of formula (x).

6. The process of claim 5 , further comprising step (c), prior to (d), of reducing a compound of formula (viii):

(i) by hydrogenation in the presence of a metal catalyst; or
(ii) with a reducing agent

to afford the compound of formula (ix).

7. The process of claim 6 , further comprising the step (b), prior to step (c), of treating a compound of formula (vii) with a mono-substituted guanidine of formula (xix):

to afford the compound of formula (viii).

8. The process of claim 7 , further comprising the step (a), prior to step (b), of providing a compound of formula (vi):

and treating the compound of formula (vi) with N,N-dimethylformamide dimethyl acetal to prepare the compound of formula (vii) for use in step (b).

9. A process for preparing a compound of formula (A-1):

or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;
Ring B is a substituted or unsubstituted aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;
Ring C is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;
R e is hydrogen, —OR 5 , —N(R 4 ) 2 , —SR 5 , or a C 1-3 aliphatic optionally substituted with R 3 or R 7 ;
each of R x and R y independently is hydrogen, fluoro, or an optionally substituted C 1-6 aliphatic; or R x and R y , taken together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloaliphatic ring;
each R 3 independently is selected from the group consisting of halo, —OH, —O(C 1-3 alkyl), —CN, —N(R 4 ) 2 , —C(O)(C 1-3 alkyl), —CO 2 H, —CO 2 (C 1-3 alkyl), —C(O)NH 2 , and —C(O)NH(C 1-3 alkyl);
each R 4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R 4 on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;
each R 5 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; and
each R 7 independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group;
said process comprising step (g) of cross-coupling a compound of formula (xviii):

with an organoboronic acid using palladium catalysis to afford the compound of formula (A-1).

10. The process of claim 9 , further comprising step (f), prior to step (g), of treating a compound of formula (xvii):

with a chlorinating reagent to afford the compound of formula (xviii).

11. The process of claim 10 , further comprising step (e), prior to step (f), of treating a compound of formula (xvi) with a mono-substituted guanidine of formula (xix):

to afford the compound of formula (xvii).

12. The process of claim 11 , fu

Assignees

• Millennium Pharm Inc

Inventors

• Claiborne Christopher F
• Payne Lloyd J
• Boyce Richard J
• Sells Todd B
• Stroud Stephen G
• Travers Stuart
• Vos Tricia J
• Weatherhead Gabriel S

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D487/14 Primary

  Ortho-condensed systems · CPC title

• C07D495/14

  Ortho-condensed systems · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title